In this study, our aim was to evaluate the potential therapeutic benefits of combining PI3K inhibitors with a cyclin−dependent kinase inhibitor in the context of metastatic cSCC using relevant cell line models of the disease. Here, PIK3CA is linked to skin squamous cell carcinoma.